(Total Views: 334)
Posted On: 05/30/2019 11:36:03 AM
Post# of 154919
Re: ClosetInvestor #3661
Pembrolizumab is the newest approved colon cancer drug (approved only for MSI-H CRC) - 32% ORR, 3% CRR. 64% AE, 3% SAE. Survival rate at 12 months not statistically significant (76%).
With 27,000 new metastatic colon cancer patients each year in the U.S. and metastatic colon cancer having only a 14% - 5 year survival rate, it is where our star will shine.
With 27,000 new metastatic colon cancer patients each year in the U.S. and metastatic colon cancer having only a 14% - 5 year survival rate, it is where our star will shine.
(0)
(0)
